Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Annaly Capital Management, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Annaly Capital Management, Inc. trades at $22.89 (market cap $16.75B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.4× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays a 13.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NLY | |
|---|---|---|
Market Cap | $39.89B | $16.75B |
Sector | Health | Financials |
52-Week High | $491.22 | $24.40 |
52-Week Low | $278.09 | $19.47 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 13.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Annaly Capital Management (NLY) trades at $22.86, up 0.57% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 91.17% net income margin and 15.61% ROE, supported by a recent dividend increase to $0.75 per share. Analyst consensus is bullish with a $24.40 price target, reflecting confidence in its mortgage REIT model amid evolving Fed policy.
NLY offers a high-yield opportunity with manageable risks from interest rate sensitivity. The stock's attractive valuation (P/E 7.37, P/B 1.16) and positive cash flow trends support upside potential, though investors must monitor leverage and macroeconomic shifts that impact mortgage spreads and refinancing activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
